Trial Profile

A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HH-CYH33 (Primary)
Indications Advanced breast cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Haihe Biopharma; ShangHai HaiHe Pharmaceutical

30 Apr 2025 Results evaluating Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 presented at the 116th Annual Meeting of the American Association for Cancer Research.
22 Apr 2025 Status changed from recruiting to completed.
04 Jan 2023 Planned End Date changed from 20 Aug 2021 to 31 Mar 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com